1411 ET - Elevance Health cut its guidance by slightly more than expected, but still within the realm of possibilities investors anticipated, Guggenheim analysts say in a note. Shares could be volatile given the updated outlook, but in the longer term, the new $30 2025 adjusted EPS baseline should give the stock a more attractive jump-off for next year, given the importance of health insurance exchange repricing and normalizing Medicaid costs for the company's long-term earnings growth target, the analysts say. Elevance slides 11%. (kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
July 17, 2025 14:11 ET (18:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.